<p>Korro Bio（納斯達克代碼：KRRO - 獲取免費報告）於週三發佈了季度財報。該公司報告每股收益（EPS）為（$1.92），超出分析師一致預期的（$2.61）$0.69，Zacks 報道。</p>
<h2>Korro Bio 股價下跌 4.2%</h2>
<ul>
<li>三隻可能因歐洲銀行降息而上漲的股票</li>
</ul>
<p>週三午盤交易中，Korro Bio 股票下跌 $1.38，報 $31.42。該公司的交易量為 1,634,378 股，而其平均交易量為 190,818 股。該公司的 50 日簡單移動平均線為 $38.69，200 日簡單移動平均線為 $23.58。Korro Bio 的一年低點為 $10.29，一年高點為 $70.49。</p>
<h2>分析師評級上調與下調</h2>
<p>幾位研究分析師最近對 KRRO 股票發表了看法。Raymond James Financial 將 Korro Bio 的目標價從 $153.00 下調至 $147.00，並在 8 月 13 日的研究報告中給予該股票 &#34;強力買入&#34; 評級。HC Wainwright 將 Korro Bio 的目標價從 $100.00 下調至 $90.00，並在 8 月 13 日的報告中給予該股票 &#34;買入&#34; 評級。Weiss Ratings 在 10 月 14 日的研究報告中重新發布了對 Korro Bio 股票的 &#34;賣出（d-）&#34; 評級。最後，Chardan Capital 在 8 月 13 日的研究報告中重申了 &#34;買入&#34; 評級，並對 Korro Bio 股票設定了 $25.00 的目標價。兩位投資分析師給予該股票 &#34;強力買入&#34; 評級，五位給予 &#34;買入&#34; 評級，一位給予 &#34;賣出&#34; 評級。根據 MarketBeat.com 的數據，Korro Bio 的一致評級為 &#34;買入&#34;，一致目標價為 $86.83。</p>
<p><strong>查看我們最新的 KRRO 研究報告</strong></p>
<h2>對 Korro Bio 的對沖基金看法</h2>
<p>對沖基金最近調整了對該股票的持有。Vanguard Group Inc. 在第三季度將其在 Korro Bio 的持股增加了 2.3%。Vanguard Group Inc. 目前擁有 395,659 股該公司的股票，價值 $18,948,000，此前在上個季度購買了額外的 8,921 股。Geode Capital Management LLC 在第二季度將其在 Korro Bio 的持股增加了 10.8%。Geode Capital Management LLC 目前擁有 155,387 股該公司的股票，價值 $1,941,000，此前在上個季度購買了額外的 15,166 股。Raymond James Financial Inc. 在第二季度將其在 Korro Bio 的持股增加了 357.6%。Raymond James Financial Inc. 目前擁有 83,392 股該公司的股票，價值 $1,042,000，此前在上個季度購買了額外的 65,170 股。最後，Bank of America Corp DE 在第二季度將其在 Korro Bio 的持股增加了 520.0%。Bank of America Corp DE 目前擁有 28,156 股該公司的股票，價值 $352,000，此前在上個季度購買了額外的 23,615 股。13.18% 的股票由機構投資者和對沖基金持有。</p>
<h2>Korro Bio 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Korro Bio, Inc. 是一家生物製藥公司，專注於基於 RNA 編輯的基因藥物的發現、開發和商業化，主要用於治療稀有和高度流行的疾病，主要在美國。其主要產品候選藥物是 KRRO-110，目前正在進行 Alpha-1 抗胰蛋白酶缺乏症（AATD）的臨牀前試驗。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票而非 Korro Bio</li>
<li>消費者物價指數測量什麼？</li>
<li>稀土股票：並非真正的休戰</li>
<li>什麼是債券市場假期？如何投資和交易</li>
<li>切分利潤：感恩節餐桌上的三隻食品股票</li>
<li>最佳 ESG 股票：11 只最佳 ESG 投資股票</li>
<li>C3.ai 的重置：為何新領導層可能引發轉機</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1JSTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1JSTw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 $1,000 在 Korro Bio 嗎？</h2>
<p>在你考慮投資 Korro Bio 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議現在購買，以便在更廣泛的市場注意到之前……而 Korro Bio 並不在名單上。</p>
<p>雖然 Korro Bio 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

KRRO

<p>Korro Bio（納斯達克代碼：KRRO）報告的季度每股收益為（$1.92），超出市場共識預期的（$2.61）$0.69。儘管出現了積極的盈利意外，股價仍下跌 4.2%，至$31.42。分析師的評級意見不一，市場共識為 “買入”，目標價為$86.83。對沖基金已調整其持倉，Vanguard 和 Geode Capital 的持倉顯著增加。Korro Bio 專注於基因藥物，其主要產品 KRRO-110 正在進行針對α-1 抗胰蛋白酶缺乏症的臨牀前試驗</p>

<p>Korro Bio (NASDAQ:KRRO - Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($1.92) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.61) by $0.69, Zacks reports.</p>
<div class="lb-trans"><p>Korro Bio（納斯達克代碼：KRRO - 獲取免費報告）於週三發佈了季度財報。該公司報告每股收益（EPS）為（$1.92），超出分析師一致預期的（$2.61）$0.69，Zacks 報道。</p>
</div><h2>Korro Bio Trading Down 4.2%</h2>
<div class="lb-trans"><h2>Korro Bio 股價下跌 4.2%</h2>
</div><ul>
<li>3 Stocks That Could Rise on European Bank Interest Rate Cuts</li>
</ul>
<div class="lb-trans"><ul>
<li>三隻可能因歐洲銀行降息而上漲的股票</li>
</ul>
</div><p>Shares of Korro Bio stock traded down $1.38 during midday trading on Wednesday, hitting $31.42. The company had a trading volume of 1,634,378 shares, compared to its average volume of 190,818. The business's 50 day simple moving average is $38.69 and its two-hundred day simple moving average is $23.58. Korro Bio has a 1-year low of $10.29 and a 1-year high of $70.49.</p>
<div class="lb-trans"><p>週三午盤交易中，Korro Bio 股票下跌 $1.38，報 $31.42。該公司的交易量為 1,634,378 股，而其平均交易量為 190,818 股。該公司的 50 日簡單移動平均線為 $38.69，200 日簡單移動平均線為 $23.58。Korro Bio 的一年低點為 $10.29，一年高點為 $70.49。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調與下調</h2>
</div><p>Several research analysts recently weighed in on KRRO shares. Raymond James Financial dropped their price target on Korro Bio from $153.00 to $147.00 and set a &#34;strong-buy&#34; rating on the stock in a research report on Wednesday, August 13th. HC Wainwright dropped their target price on Korro Bio from $100.00 to $90.00 and set a &#34;buy&#34; rating on the stock in a report on Wednesday, August 13th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Korro Bio in a research report on Tuesday, October 14th. Finally, Chardan Capital reiterated a &#34;buy&#34; rating and issued a $25.00 price objective on shares of Korro Bio in a research note on Wednesday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Korro Bio has a consensus rating of &#34;Buy&#34; and a consensus price target of $86.83.</p>
<div class="lb-trans"><p>幾位研究分析師最近對 KRRO 股票發表了看法。Raymond James Financial 將 Korro Bio 的目標價從 $153.00 下調至 $147.00，並在 8 月 13 日的研究報告中給予該股票 &#34;強力買入&#34; 評級。HC Wainwright 將 Korro Bio 的目標價從 $100.00 下調至 $90.00，並在 8 月 13 日的報告中給予該股票 &#34;買入&#34; 評級。Weiss Ratings 在 10 月 14 日的研究報告中重新發布了對 Korro Bio 股票的 &#34;賣出（d-）&#34; 評級。最後，Chardan Capital 在 8 月 13 日的研究報告中重申了 &#34;買入&#34; 評級，並對 Korro Bio 股票設定了 $25.00 的目標價。兩位投資分析師給予該股票 &#34;強力買入&#34; 評級，五位給予 &#34;買入&#34; 評級，一位給予 &#34;賣出&#34; 評級。根據 MarketBeat.com 的數據，Korro Bio 的一致評級為 &#34;買入&#34;，一致目標價為 $86.83。</p>
</div><p><strong>View Our Latest Research Report on KRRO</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 KRRO 研究報告</strong></p>
</div><h2>Hedge Funds Weigh In On Korro Bio</h2>
<div class="lb-trans"><h2>對 Korro Bio 的對沖基金看法</h2>
</div><p>Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. grew its holdings in shares of Korro Bio by 2.3% in the 3rd quarter. Vanguard Group Inc. now owns 395,659 shares of the company's stock worth $18,948,000 after purchasing an additional 8,921 shares during the last quarter. Geode Capital Management LLC boosted its position in Korro Bio by 10.8% in the second quarter. Geode Capital Management LLC now owns 155,387 shares of the company's stock valued at $1,941,000 after buying an additional 15,166 shares in the last quarter. Raymond James Financial Inc. grew its stake in Korro Bio by 357.6% during the second quarter. Raymond James Financial Inc. now owns 83,392 shares of the company's stock worth $1,042,000 after buying an additional 65,170 shares during the last quarter. Finally, Bank of America Corp DE increased its holdings in shares of Korro Bio by 520.0% during the second quarter. Bank of America Corp DE now owns 28,156 shares of the company's stock worth $352,000 after buying an additional 23,615 shares in the last quarter. 13.18% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>對沖基金最近調整了對該股票的持有。Vanguard Group Inc. 在第三季度將其在 Korro Bio 的持股增加了 2.3%。Vanguard Group Inc. 目前擁有 395,659 股該公司的股票，價值 $18,948,000，此前在上個季度購買了額外的 8,921 股。Geode Capital Management LLC 在第二季度將其在 Korro Bio 的持股增加了 10.8%。Geode Capital Management LLC 目前擁有 155,387 股該公司的股票，價值 $1,941,000，此前在上個季度購買了額外的 15,166 股。Raymond James Financial Inc. 在第二季度將其在 Korro Bio 的持股增加了 357.6%。Raymond James Financial Inc. 目前擁有 83,392 股該公司的股票，價值 $1,042,000，此前在上個季度購買了額外的 65,170 股。最後，Bank of America Corp DE 在第二季度將其在 Korro Bio 的持股增加了 520.0%。Bank of America Corp DE 目前擁有 28,156 股該公司的股票，價值 $352,000，此前在上個季度購買了額外的 23,615 股。13.18% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Korro Bio Company Profile</h2>
<div class="lb-trans"><h2>Korro Bio 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).</p>
<div class="lb-trans"><p>Korro Bio, Inc. 是一家生物製藥公司，專注於基於 RNA 編輯的基因藥物的發現、開發和商業化，主要用於治療稀有和高度流行的疾病，主要在美國。其主要產品候選藥物是 KRRO-110，目前正在進行 Alpha-1 抗胰蛋白酶缺乏症（AATD）的臨牀前試驗。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Korro Bio</li>
<li>What does consumer price index measure?</li>
<li>Rare Earth Stocks: The Truce That Isn't a Truce</li>
<li>What is a Bond Market Holiday? How to Invest and Trade</li>
<li>Carving Up Profits: 3 Food Stocks on the Thanksgiving Table</li>
<li>Best ESG Stocks: 11 Best Stocks for ESG Investing</li>
<li>C3.ai's Reset: Why New Leadership Could Spark a Turnaround</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票而非 Korro Bio</li>
<li>消費者物價指數測量什麼？</li>
<li>稀土股票：並非真正的休戰</li>
<li>什麼是債券市場假期？如何投資和交易</li>
<li>切分利潤：感恩節餐桌上的三隻食品股票</li>
<li>最佳 ESG 股票：11 只最佳 ESG 投資股票</li>
<li>C3.ai 的重置：為何新領導層可能引發轉機</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1JSTw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=KRRO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Korro Bio Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Korro Bio 嗎？</h2>
</div><p>Before you consider Korro Bio, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮投資 Korro Bio 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Korro Bio wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議現在購買，以便在更廣泛的市場注意到之前……而 Korro Bio 並不在名單上。</p>
</div><p>While Korro Bio currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Korro Bio 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Korro Bio（納斯達克股票代碼：KRRO）公佈財報，每股收益超出預期 0.69 美元